Drug and Alcohol Dependence
Volume 105, Issue 1 , Pages 83-88 , 1 November 2009

Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a Nationwide Survey

  • Amy Nunn

      Affiliations

    • Alpert Medical School of Brown University, Division of Infectious Diseases, 164 Summit Avenue, Providence, RI 02906, USA
    • The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
    • Corresponding Author InformationCorresponding author at: Alpert Medical School of Brown University, Division of Infectious Diseases, 164 Summit Avenue, Providence, RI 02906, USA.
    • ,
  • Nickolas Zaller

      Affiliations

    • Alpert Medical School of Brown University, Division of Infectious Diseases, 164 Summit Avenue, Providence, RI 02906, USA
    • The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
    • Center for Prisoner Health and Human Rights, USA
    • ,
  • Samuel Dickman

      Affiliations

    • Alpert Medical School of Brown University, Division of Infectious Diseases, 164 Summit Avenue, Providence, RI 02906, USA
    • ,
  • Catherine Trimbur

      Affiliations

    • University of Rochester School of Medicine and Dentistry, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
    • ,
  • Ank Nijhawan

      Affiliations

    • Alpert Medical School of Brown University, Division of Infectious Diseases, 164 Summit Avenue, Providence, RI 02906, USA
    • The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
    • ,
  • Josiah D. Rich

      Affiliations

    • Alpert Medical School of Brown University, Division of Infectious Diseases, 164 Summit Avenue, Providence, RI 02906, USA
    • The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
    • Center for Prisoner Health and Human Rights, USA

Received 24 December 2008 ,Revised 11 June 2009 ,Accepted 12 June 2009.

References 

  1. Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. Am. J. Addict. 2004;13(Suppl. 1):S17–S28
  2. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA. 2001;285:45
  3. Bick J. HIV and Viral Hepatitis in Corrections: A Public Health Opportunity. In:  Greifinger R editors. Public Health Behind Bars. New York: Springer International; 2007;
  4. Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison—a high risk of death for former inmates. N. Engl. J. Med. 2007;356:157–165
  5. Bird SM, Hutchinson SJ. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996–99. Addiction. 2003;98:185–190
  6. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin. Infect. Dis. 2006;43(Suppl. 4):S197–S215
  7. CDC, 2002. Substance abuse treatment for injecting drug users: a strategy with many benefits. Centers for Disease Control and Prevention, Atlanta.
  8. CEC, 2007. Report from the Commission to the European Parliament and the Council on the implementation of the Council Recommendation of 18 June 2003 on the prevention and reduction of health-related harm associated with drug dependence. Commission of the European Communities.
  9. Clarke JG, Stein MD, Hanna L, Sobota M, Rich JD. Active and former injection drug users report of HIV risk behaviors during periods of incarceration. Subst. Abus. 2001;22:209–216
  10. Comer SD, Collins ED. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J. Pharmacol. Exp. Ther. 2002;303:695–703
  11. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100:820–828
  12. Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N. Engl. J. Med. 1969;280:1372–1375
  13. Drucker E. Drug prohibition and public health: 25 years of evidence. Public Health Rep. 1999;114:14–29
  14. Fallon BM. The Key Extended Entry Program (KEEP): from the community side of the bridge. Mt. Sinai J. Med. 2001;68:21–27
  15. Fhima A, Henrion R, Lowenstein W, Charpak Y. Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex). Ann. Med. Interne. (Paris). 2001;152(Suppl. 3):IS26–S36
  16. Fiellin DA, O’Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N. Engl. J. Med. 2002;347:817–823
  17. Freudenberg N. Jails, prisons, and the health of urban populations: a review of the impact of the correctional system on community health. J. Urban Health. 2001;78:214–235
  18. Gerra G, Ferri M, Polidori E, Santoro G, Zaimovic A, Sternieri E. Long-term methadone maintenance effectiveness: psychosocial and pharmacological variables. J. Subst. Abuse Treat. 2003;25:1–8
  19. Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction. 2008;103:1333–1342
  20. Gore SM, Bird AG, Burns SM, Goldberg DJ, Ross AJ, Macgregor J. Drug injection and HIV prevalence in inmates of Glenochil prison. BMJ. 1995;310:293–296
  21. Greifinger R. Thirty Years Since Estelle v. Gamble. In:  Greifinger R editors. Public Health Behind Bars: From Prisons to Communities. New York: Springer International; 2007;
  22. Hammett TM. HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response. Am. J. Public Health. 2006;96:974–978
  23. Hanlon TE, Nurco DN, Kinlock TW, Duszynski KR. Trends in criminal activity and drug use over an addiction career. Am. J. Drug Alcohol Abuse. 1990;16:223–238
  24. Heimer R, Catania H, Newman RG, Zambrano J, Brunet A, Ortiz AM. Methadone maintenance in prison: evaluation of a pilot program in Puerto Rico. Drug Alcohol Depend. 2006;83:122–129
  25. Inciardi JA, Needle RH. Editors’ introduction: HIV/AIDS interventions for out-of-treatment drug users. J. Psychoactive Drugs. 1998;30:225–229
  26. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361:662–668
  27. Kang SY, Deren S, Andia J, Colon HM, Robles R, Oliver-Velez D. HIV transmission behaviors in jail/prison among Puerto Rican drug injectors in New York and Puerto Rico. AIDS Behav. 2005;9:377–386
  28. Kinlock TW, Battjes RJ, Schwartz RP. A novel opioid maintenance program for prisoners: preliminary findings. J. Subst. Abuse Treat. 2002;22:141–147
  29. Kinlock TW, Gordon MS, Schwartz RP, O’Grady K. A study of methadone maintenance for male prisoners: 3 month post-release outcomes. Crim. Justice Behav. 2008;35:34–47
  30. Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE. A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Crim. Justice Behav. 2008;35:34–47
  31. Krebs CP, Simmons M. Intraprison HIV transmission: an assessment of whether it occurs, how it occurs, and who is at risk. AIDS Educ. Prev. 2002;14:53–64
  32. Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 1992;70:205–230
  33. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann. N Y Acad. Sci. 2000;909:186–216
  34. Krinsky CS, Lathrop SL, Brown P, Nolte KB. Drugs, detention, and death: a study of the mortality of recently released prisoners. Am. J. Forensic Med. Pathol. 2009;30:6–9
  35. Lipton DS. Correctional drug abuse treatment in the United States: an overview. In:  Leukefeld CG,  Tims FM editor. Drug Abuse Treatment in Prisons and Jails. Washington, DC: National Institute on Drug Abuse Research Monograph Series; 1992;
  36. Marsch L. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93:515–532
  37. Martin S. Three year outcomes of therapeutic community treatment for drug-involved offenders in Delaware: From prison to work release to aftercare. The Prison J. 1999;79
  38. McKenzie M, Macalino G, McClung C, Shield DC, Rich JD. Opiate replacement therapy at time of release from incarceration: Project MOD, a pilot program. J. Opioid Manage. 2005;1:147–151
  39. McLellan AT, Arndt IO, Metzger DS, Woody GE, O’Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953–1959
  40. Møller L, Stöver H, Jürgens R, Gatherer A, Nikogosian H. Health in Prisons: A WHO Guide to the Essentials in Prison Health. Geneva: World Health Organization; 2007;
  41. Mumola C, Karberg J. Drug Use and Dependence, State and Federal Prisoners. Washington, DC: U.S. Department of Justice, Office of Justice Programs; 2006;
  42. Nurco DN, Hanlon TE, Kinlock TW. Recent research on the relationship between illicit drug use and crime. Behav. Sci. Law. 1991;9:221–242
  43. Rich JD, Boutwell AE, Shield DC, Key RG, McKenzie M, Clarke JG, et al. Attitudes and practices regarding the use of methadone in US state and federal prisons. J. Urban Health. 2005;82:411–419
  44. Rich JD, McKenzie M, Shield DC, Wolf FA, Key RG, Poshkus M, et al. Linkage with methadone treatment upon release from incarceration: a promising opportunity. J. Addict. Dis. 2005;24:49–59
  45. Sabol, W., Couture, H., 2008. Prison Inmates at Midyear 2007. US Department of Justice.
  46. SAMHSA, 2007. National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Washington DC.
  47. Seal DW, Margolis AD, Morrow KM, Belcher L, Sosman J, Askew J. Substance use and sexual behavior during incarceration among 18- to 29-year old men: prevalence and correlates. AIDS Behav. 2008;12:27–40
  48. Springer S, Altice F. Improving the Care for HIV-infected Prisoners Public Health Behind Bars. New York: Springer; 2007;pp. 535–555
  49. Visher C, Mallik-Cane K. Reentry experiences of men with health problems. In:  Greifinger R editors. Public Health Behind Bars. New Yorker: Springer International; 2007;
  50. Walmsley, R., 2008. World Prison Population List. Kings College of London International Centre for Prison Studies, London.
  51. WHO, 2005. WHO Status Paper on Prisons, Drugs and Harm Reduction.
  52. WHO . Interventions to Address HIV in Prison: Drug Dependence Treatment. Geneva: World Health Organization; 2007;

PII: S0376-8716(09)00237-3

doi: 10.1016/j.drugalcdep.2009.06.015

Drug and Alcohol Dependence
Volume 105, Issue 1 , Pages 83-88 , 1 November 2009

Article Tools

* Image Usage & Resolution